100 related articles for article (PubMed ID: 23566417)
1. αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma.
Ducassou A; Uro-Coste E; Verrelle P; Filleron T; Benouaich-Amiel A; Lubrano V; Sol JC; Delisle MB; Favre G; Ken S; Laprie A; De Porre P; Toulas C; Poublanc M; Cohen-Jonathan Moyal E
Eur J Cancer; 2013 Jun; 49(9):2161-9. PubMed ID: 23566417
[TBL] [Abstract][Full Text] [Related]
2. Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB.
Monferran S; Skuli N; Delmas C; Favre G; Bonnet J; Cohen-Jonathan-Moyal E; Toulas C
Int J Cancer; 2008 Jul; 123(2):357-364. PubMed ID: 18464290
[TBL] [Abstract][Full Text] [Related]
3. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
[TBL] [Abstract][Full Text] [Related]
4. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
Weller M; Nabors LB; Gorlia T; Leske H; Rushing E; Bady P; Hicking C; Perry J; Hong YK; Roth P; Wick W; Goodman SL; Hegi ME; Picard M; Moch H; Straub J; Stupp R
Oncotarget; 2016 Mar; 7(12):15018-32. PubMed ID: 26918452
[TBL] [Abstract][Full Text] [Related]
5. Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.
Usul Afsar C; Sahin B; Gunaldi M; Kılıc Bagir E; Gumurdulu D; Burgut R; Erkisi M; Kara IO; Paydas S; Karaca F; Ercolak V
Int J Clin Exp Pathol; 2015; 8(9):9760-71. PubMed ID: 26617686
[TBL] [Abstract][Full Text] [Related]
6. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
[TBL] [Abstract][Full Text] [Related]
8. Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease.
Lustig R; Mikkelsen T; Lesser G; Grossman S; Ye X; Desideri S; Fisher J; Wright J;
Neuro Oncol; 2008 Dec; 10(6):1004-9. PubMed ID: 18725460
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
[TBL] [Abstract][Full Text] [Related]
10. Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.
Skuli N; Monferran S; Delmas C; Favre G; Bonnet J; Toulas C; Cohen-Jonathan Moyal E
Cancer Res; 2009 Apr; 69(8):3308-16. PubMed ID: 19351861
[TBL] [Abstract][Full Text] [Related]
11. Subventricular zones: new key targets for glioblastoma treatment.
Khalifa J; Tensaouti F; Lusque A; Plas B; Lotterie JA; Benouaich-Amiel A; Uro-Coste E; Lubrano V; Cohen-Jonathan Moyal E
Radiat Oncol; 2017 Apr; 12(1):67. PubMed ID: 28424082
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme.
Moyal EC; Laprie A; Delannes M; Poublanc M; Catalaa I; Dalenc F; Berchery D; Sabatier J; Bousquet P; De Porre P; Alaux B; Toulas C
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1396-401. PubMed ID: 17570606
[TBL] [Abstract][Full Text] [Related]
13. Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy.
Wang W; Zhu NL; Chua J; Swenson S; Costa FK; Schmitmeier S; Sosnowski BA; Shichinohe T; Kasahara N; Chen TC
J Neurosurg; 2005 Dec; 103(6):1058-66. PubMed ID: 16381193
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY
J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196
[TBL] [Abstract][Full Text] [Related]
15. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.
Lamfers ML; Grill J; Dirven CM; Van Beusechem VW; Geoerger B; Van Den Berg J; Alemany R; Fueyo J; Curiel DT; Vassal G; Pinedo HM; Vandertop WP; Gerritsen WR
Cancer Res; 2002 Oct; 62(20):5736-42. PubMed ID: 12384532
[TBL] [Abstract][Full Text] [Related]
16. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation.
Anderson HJ; Galileo DS
Cell Oncol (Dordr); 2016 Jun; 39(3):229-42. PubMed ID: 26883759
[TBL] [Abstract][Full Text] [Related]
18. Expression of integrins αvβ3 and αvβ5 and their ligands in primary and secondary central nervous system neoplasms.
Mittelbronn M; Warth A; Meyermann R; Goodman S; Weller M
Histol Histopathol; 2013 Jun; 28(6):749-58. PubMed ID: 23238957
[TBL] [Abstract][Full Text] [Related]
19. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article.
Muragaki Y; Maruyama T; Iseki H; Tanaka M; Shinohara C; Takakura K; Tsuboi K; Yamamoto T; Matsumura A; Matsutani M; Karasawa K; Shimada K; Yamaguchi N; Nakazato Y; Sato K; Uemae Y; Ohno T; Okada Y; Hori T
J Neurosurg; 2011 Aug; 115(2):248-55. PubMed ID: 21568657
[TBL] [Abstract][Full Text] [Related]
20. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
